Pemetrexed-Induced fluid retention

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 752-

  Bastos, Diogo Assed ^a   Calabrich, Aknar ^a   Katz, Artur ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PEMETREXED;

DRUG WITHDRAWAL; FLUID RETENTION; HUMAN; LETTER; PERIORBITAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; THORACOCENTESIS;

EID: 77951785846     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d6b9e8     Document Type: Letter

References (4)

1. Hanna N, Shepherd FA, Fossella FW, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
2. Russo F, Bearz A, Pampaloni G. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic nonsmall cell lung cancer. BMC Cancer 2008;8:216.
3. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397-401.
4. Kurata T, Tamura K, Okamoto I, et al. Pemetrexed- induced edema of the eyelid. Lung Cancer 2006;54:241-242.